GEMALTO
3.4.2018 07:02:11 CEST | Business Wire | Press release
Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, today announced that SafeNet KeySecure has been validated for use with the latest release of NetApp® Volume Encryption (NVE) data management solution. As a result, NetApp customers do not need to encrypt the entire disk drive; they can choose to encrypt granularly at the volume level without the need and additional cost of purchasing self encrypting drives (SEDs), while retaining key benefits such as centralized key management and access control, better compliance, and high availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005033/en/
Data privacy and data security continues to be a key focus for organizations, especially in light of industry compliance standards such as US health standard (HIPAA) or payment card standard (PCI-DSS) and the EU’s General Data Protection Regulation (GDPR ). SafeNet KeySecure centralizes cryptographic processing, security policy and key management, while offering NetApp customers the ability to store and manage encryption keys centrally and separately, away from the encrypted data ensuring security and facilitating compliance.
“Data has become one of the most valuable assets for organizations, but as with anything with value, criminals are determined to get their hands on it,” said Todd Moore, Gemalto Senior Vice President for Encryption Products. “With legislation forcing companies to reveal breaches such as the GDPR, which is due to come into effect in May, there will be nowhere for organizations to hide. This increase in attention means that they must find a way to control who has access to their data and ensure they’re putting in the necessary tools to protect it.”
The Gemalto SafeNet KeySecure solution builds on the NetApp Data Fabric software approach, which simplifies and integrates data management across the cloud and on premises to accelerate digital transformation. On top of having more granular data encryption and keeping keys separate, customers will have the freedom to choose any storage media, have flexible deployment options, audit trails, separation of duties and ecosystem support.
“The NetApp Alliance Partner Program enables us to join forces with the best and brightest in the industry, to address the storage and data infrastructure needs of today’s complex enterprise environments,” said Deepak Visweswaraiah, Senior Vice President, Manageability Products and Solutions Group, at NetApp. “As a result of working with the world leader in digital security, we can now offer our customers peace-of-mind that their data is safe and compliant.”
For more information on Gemalto SafeNet KeySecure:
- Read this blog: Benefits of External Key Management for Storage
- Download the SafeNet KeySecure and SafeNet Virtual KeySecure product briefs
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005033/en/
Contact:
Gemalto media contacts:
Tauri Cox
North America
+1
512 257 3916
tauri.cox@gemalto.com
or
Sophie
Dombres
Europe Middle East & Africa
+33 4 42 55 36 57 38
sophie.dombres@gemalto.com
or
Jaslin
Huang
Asia Pacific
+65 6317 3005
jaslin.huang@gemalto.com
or
Enriqueta
Sedano
Latin America
+52 5521221422
enriqueta.sedano@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom